Pre-order Enquiry
Request Free Sample
Global Traveler's Diarrhea Therapeutics Market Growth 2019-2024
SKU ID : LPI-13763943 | Publishing Date : 23-Jan-2019 | No. of pages : 139
Traveler's diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. It may be accompanied by abdominal cramps, nausea, fever, and bloating. Occasionally bloody diarrhea may occur. Most travelers recover within four days with little or no treatment. About 10% of people may have symptoms for a week.
Traveler’s diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. Among the estimated 65 million travelers from industrialized countries to high-risk areas in the developing world, as many as 50% may experience at least one TD episode during their journey. ETEC is usually responsible for 22-60% of all TD cases in both civilian and military groups or about 7-18 million cases per year. ETEC is also a major cause of diarrheal disease in children living in countries endemic for ETEC, leading to over 400 million diarrheal episodes and approximately 300,000 deaths each year.
The classification of Traveler’s Diarrhea Therapeutics includes Immunization, Non-antibiotic Agents, Antibiotics, Anti-Motility Agents, Other. And the proportion of Non-antibiotic Agents in 2017 is about 36%, and And the proportion of Anti-Motility Agents in 2017 is about 20%.
According to this study, over the next five years the Traveler's Diarrhea Therapeutics market will register a 7.1% CAGR in terms of revenue, the global market size will reach US$ 890 million by 2024, from US$ 630 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Traveler's Diarrhea Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Traveler's Diarrhea Therapeutics market by product type, application, key manufacturers and key regions and countries.
This study considers the Traveler's Diarrhea Therapeutics value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Immunization
Non-antibiotic Agents
Antibiotics
Anti-Motility Agents
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Adult Traveler's Diarrhea
Children Traveler's Diarrhea
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Salix Pharmaceuticals
P&G
Johnson & Johnson
Otsuka Pharma
Valneva
Shanghai United Cell
PaxVax
Livzon
Immuron
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Traveler's Diarrhea Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Traveler's Diarrhea Therapeutics market by identifying its various subsegments.
Focuses on the key global Traveler's Diarrhea Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Traveler's Diarrhea Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Traveler's Diarrhea Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Traveler’s diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. Among the estimated 65 million travelers from industrialized countries to high-risk areas in the developing world, as many as 50% may experience at least one TD episode during their journey. ETEC is usually responsible for 22-60% of all TD cases in both civilian and military groups or about 7-18 million cases per year. ETEC is also a major cause of diarrheal disease in children living in countries endemic for ETEC, leading to over 400 million diarrheal episodes and approximately 300,000 deaths each year.
The classification of Traveler’s Diarrhea Therapeutics includes Immunization, Non-antibiotic Agents, Antibiotics, Anti-Motility Agents, Other. And the proportion of Non-antibiotic Agents in 2017 is about 36%, and And the proportion of Anti-Motility Agents in 2017 is about 20%.
According to this study, over the next five years the Traveler's Diarrhea Therapeutics market will register a 7.1% CAGR in terms of revenue, the global market size will reach US$ 890 million by 2024, from US$ 630 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Traveler's Diarrhea Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Traveler's Diarrhea Therapeutics market by product type, application, key manufacturers and key regions and countries.
This study considers the Traveler's Diarrhea Therapeutics value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Immunization
Non-antibiotic Agents
Antibiotics
Anti-Motility Agents
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Adult Traveler's Diarrhea
Children Traveler's Diarrhea
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Salix Pharmaceuticals
P&G
Johnson & Johnson
Otsuka Pharma
Valneva
Shanghai United Cell
PaxVax
Livzon
Immuron
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Traveler's Diarrhea Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Traveler's Diarrhea Therapeutics market by identifying its various subsegments.
Focuses on the key global Traveler's Diarrhea Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Traveler's Diarrhea Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Traveler's Diarrhea Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
